Group 1: 盈方微重大资产重组 - 盈方微 is planning to acquire controlling stakes in Shanghai Xiaokeli Information Technology Co., Ltd., FIRST TECHNOLOGY CHINA LIMITED, and Shiqing Intelligent Technology (Shanghai) Co., Ltd., which is expected to constitute a major asset restructuring [1][3] - The acquisition will be conducted through a combination of issuing shares and/or cash payments, and the company has announced a stock suspension starting January 6, 2026, due to uncertainties surrounding the transaction [2][3] - The company aims to disclose the transaction plan within 10 trading days, by January 20, 2026, and if not completed, the stock will resume trading on January 20, 2026, and the restructuring plans will be terminated [3] Group 2: 威高血净重大资产重组 - 威高血净 plans to issue shares to acquire 100% equity of 威高普瑞 from 威高股份, 威海盛熙, and 威海瑞明 for approximately ¥85.11 billion, which constitutes a major asset restructuring and related party transaction [8][9] - After the transaction, 威高股份 and its concerted parties will hold 84.36% of 威高血净's shares, maintaining absolute control over the company [9] - 威高普瑞, established in September 2018, specializes in the research, production, and sales of pre-filled drug delivery systems and automatic safety drug delivery systems, which will expand 威高血净's product offerings in the pharmaceutical packaging sector [10][11]

【导读】盈方微筹划重大资产重组，计划自1月6日开市起停牌 中国基金报记者 闻言 1月5日晚间，盈方微发布公告称，公司正在筹划以发行股份和/或支付现金相结合的方式，购买资产并 募集配套资金的事项，预计构成重大资产重组。 盈方微计划自1月6日开市起停牌。1月5日收盘，盈方微股价报7.73元/股，涨幅达4.74%，总市值为65.28 亿元。 图方微 7 7 陈尼 000670 深股通 L1 ▼ 今开 7.56 最高 7.75 最低 7.47 7.73 4.74% 0.35 换手⊙ 4.80% 总手 39.44万 金额 3.01亿 更多 息值⊙65.28亿 流值 63.51亿 市盈 ⊙ -112.96 ◀ 停复牌:自2026-01-06至2026-01-19连续停牌 ... ● × 分时 五日 日K 周K 月K 更多 Q 均线▼ MA5:7.48↑ 10:7.43↑ 20:7.44↑ 20:7.44↑ 20:7.43 1 前复权 10.35-10.35 7.90 7.08 主力意愿 ▼ 解锁查看完整K线数据 1023.45 17.81 20251120 20250825 20260105 20251009 拟收购三家 ...

Group 1 - Victory Energy announced that its stock price increased by 213.97% from December 12 to December 29, 2025, leading to a review of trading fluctuations, with stock resuming trading on January 6, 2026 [2] - Tianqi Materials plans to conduct maintenance on its 150,000-ton liquid lithium hexafluorophosphate production line for 20 to 30 days, ensuring no significant impact on operations [3] - Yingfang Micro is planning to acquire controlling stakes in several companies, leading to a significant asset restructuring, with stock suspension starting January 6, 2026 [4] Group 2 - Weigao Blood Purification intends to acquire 100% of Weigao Purui for 8.511 billion yuan, which will enhance its product offerings in medical packaging [6] - Zhongtian Rocket reported losses in its carbon/carbon thermal field materials business due to intensified competition in the photovoltaic industry, significantly impacting its consolidated financial statements [7] - Fulin Precision plans to invest 6 billion yuan in a project to produce 500,000 tons of high-end lithium iron phosphate for energy storage, alongside additional projects for precursor materials [8] Group 3 - Deyun Co. announced that its actual controller was arrested for illegal public deposit collection, but this will not significantly affect the company's governance or operations [9] - Jushen Co. signed a 1.34 billion USD bauxite transfer agreement, which is expected to positively impact future financial performance [10] - Sanxia New Materials intends to acquire a 40% stake in a subsidiary for 0 yuan, which is classified as a related party transaction [11] Group 4 - Kelun Pharmaceutical plans to repurchase shares worth 50 million to 100 million yuan for employee stock ownership plans, with a maximum price of 35 yuan per share [13] - Juxing Technology expects a net profit increase of 5.00% to 20.00% for 2025, projecting a profit of 2.419 billion to 2.764 billion yuan [15] - China National Materials Technology anticipates a net profit increase of 73.79% to 118.64% for 2025, driven by improved product structure and sales growth [16] Group 5 - Chifeng Gold forecasts a net profit increase of 70% to 81% for 2025, with gold product sales prices rising approximately 49% [17] - Dingtai High-Tech expects a net profit of 410 million to 460 million yuan for 2025, reflecting an 81% to 103% increase due to rising demand in high-end PCB markets [18] - Zhonggang Luoyang announced plans for shareholders to reduce their stakes by up to 1% of total shares [20]

Core Viewpoint - Yingfang Micro is planning a significant asset restructuring, intending to acquire controlling stakes in three companies and raise matching funds through a combination of share issuance and cash payments [3][9]. Group 1: Asset Restructuring Announcement - On January 5, Yingfang Micro announced that it would suspend trading starting January 6 due to the planned asset restructuring [6]. - The company's stock closed at 7.73 yuan per share, with a 4.74% increase, bringing its total market capitalization to 6.528 billion yuan [6]. Group 2: Target Companies for Acquisition - The targeted assets for acquisition include: - Shanghai Xiaokeli Information Technology Co., Ltd. - FIRST TECHNOLOGY CHINA LIMITED - Shiqing Intelligent Technology (Shanghai) Co., Ltd. [9] - The company has signed cooperation letters with shareholders of these firms to expedite the auditing and evaluation process for the transaction [9]. Group 3: Business Context and Financial Performance - Yingfang Micro has been experiencing continuous losses in its main business, which focuses on integrated circuit chip design and electronic component distribution [10]. - The company's net profit after deducting non-recurring gains and losses has shown negative figures for the years 2022 to 2024, with figures of -25.32 million yuan in 2022, -60.53 million yuan in 2023, and -63.43 million yuan projected for 2024 [10][13].

Group 1: 盈方微重大资产重组 - 盈方微 is planning to acquire controlling stakes in Shanghai Xiaokeli Information Technology Co., Ltd., FIRST TECHNOLOGY CHINA LIMITED, and Shiqing Intelligent Technology (Shanghai) Co., Ltd., which is expected to constitute a major asset restructuring [1][6] - The acquisition will be conducted through a combination of issuing shares and/or cash payments, and the company has applied for a trading suspension starting January 6, 2026, due to uncertainties surrounding the transaction [3][7] - The company aims to disclose the transaction plan within 10 trading days, by January 20, 2026, and if not completed, the stock will resume trading on January 20, 2026, and the restructuring plans will be terminated [6][7] Group 2: 威高血净重大资产重组 - 威高血净 plans to issue shares to acquire 100% equity of 威高普瑞 from 威高股份 and other shareholders for approximately 85.11 billion CNY, which constitutes a major asset restructuring and related party transaction [12][13] - Post-transaction, 威高股份 and its concerted parties will hold 84.36% of 威高血净, maintaining absolute control without changing the company's control structure [12][13] - The acquisition will expand 威高血净's business into the pharmaceutical packaging sector, adding pre-filled drug delivery systems and automatic safety drug delivery systems to its product line [13][14]

盈方微（000670）(000670.SZ)发布公告，公司正在筹划以发行股份和/或支付现金相结合的方式购买资 产并募集配套资金的事项。标的资产为上海肖克利信息科技股份有限公司、FIRST TECHNOLOGY CHINA LIMITED(富士德中国有限公司)、时擎智能科技(上海)有限公司的控股权。本次交易预计构成重 大资产重组。公司股票自1月6日开市起开始停牌。 ...

产品线扩展至医药包材领域 根据公告，本次交易前，威高血净主要从事血液净化领域医用制品的研发、生产和销售，并已基于自身 技术平台，完成了中空纤维病毒过滤器等生物制药滤器的技术研发与产品试制。本次交易后，威高血净 主营业务将新增预灌封给药系统及自动安全给药系统等医药包材的研发、生产与销售。 本次交易完成后，上市公司可以通过整合标的公司技术积累和产品布局，将产品线扩展到医药包材领 域。同时，通过充分协同上市公司自身中空纤维过滤技术优势与标的公司在生物制药领域的丰富客户资 源，可以实现双方在生物制药滤器业务上技术储备与客户资源的双向赋能，共同开拓以生物制药滤器为 重点的生物制药上游业务市场。 公告显示，威高普瑞由威高股份以设备出资的方式设立，设立时注册资本为1亿元。 从生产端来看，2023年、2024年以及2025年前三季度，威高普瑞的产能利用率分别为81.59%、 90.57%、89.42%，随着威高普瑞业务规模的扩大，其产能利用率呈上升趋势。2023年、2024年以及 2025年前三季度，威高普瑞产销率维持较高水平，分别为105.31%、96.91%、95.83%。 血液净化领域龙头威高血净1月5日晚公告称，公司 ...

血液净化领域龙头威高血净（603014）1月5日晚公告称，公司拟通过发行股份的方式，购买威高股份、 威海盛熙和威海瑞明3名交易对方持有的威高普瑞100%股权，交易价格为85.11亿元。此次交易预计构 成重大资产重组。 交易完成后，威高普瑞将成为威高血净全资子公司，威高血净主营业务将新增预灌封给药系统及自动安 全给药系统等医药包材的研发、生产与销售。 此次交易的三名交易对方均为上市公司实际控制人陈学利控制的企业，本次交易构成关联交易。交易完 成后，上市公司控股股东将由威高集团变更为威高股份。威高集团和威高股份均为陈学利控制的企业， 本次交易不会导致上市公司实际控制权变更。 同花顺（300033）数据显示，1月5日，威高血净涨4.69%，收报41.49元/股，市值为173.33亿元。 产品线扩展至医药包材领域 根据公告，本次交易前，威高血净主要从事血液净化领域医用制品的研发、生产和销售，并已基于自身 技术平台，完成了中空纤维病毒过滤器等生物制药滤器的技术研发与产品试制。本次交易后，威高血净 主营业务将新增预灌封给药系统及自动安全给药系统等医药包材的研发、生产与销售。 本次交易完成后，上市公司可以通过整合标的公司技 ...

人民财讯1月5日电，盈方微（000670）1月5日公告，公司正在筹划以发行股份和/或支付现金相结合的 方式购买资产并募集配套资金的事项。标的资产为上海肖克利信息科技股份有限公司、FIRST TECHNOLOGY CHINA LIMITED(富士德中国有限公司)、时擎智能科技(上海)有限公司的控股权。本次 交易预计构成重大资产重组。公司股票自1月6日开市起开始停牌。 ...

至正股份公告称，因发行股份购买资产并募集配套资金，公司新增股份分别于2025年12月15日等完成登 记，注册资本及总股本由7453.4998万元（股）增至15,270.9710万元（股）。因重大资产重组已完成， 公司置出高分子材料业务，置入半导体封装材料引线框架业务，拟变更经营范围。鉴于此，公司拟对 《公司章程》相关条款进行修订，其他条款及内容不变，以市场监管部门核准版本为准。 ...